Guardant Health, Inc. (GH)
Nasdaq · Healthcare · Diagnostics & Research
$187.22+5.30%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $25.1B
- 52-week range
- $61.00 – $187.69
- 52-week change
- +180.26%
- EPS (trailing)
- −$3.50
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $982M (+32.88%)
- Net income
- −$416M
- Operating margin
- −44.5%
- Diluted EPS
- −$3.32
- Free cash flow
- −$233M
From the company’s annual report on SEC EDGAR.
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults.
Headquarters: Palo Alto, United States · 2,490 employees · guardanthealth.com